Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bendamustine + rituximab + ibrutinib
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Bendamustine + rituximab + ibrutinib (IBR) is a combination therapy regimen that combines two chemotherapeutic agents with a targeted therapy. This regimen leverages complementary mechanisms of action: - Bendamustine is an alkylating agent that damages DNA, resulting in cancer cell death - Rituximab is a monoclonal antibody targeting CD20 on B cells - Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell receptor signaling The addition of ibrutinib to the bendamustine + rituximab (BR) backbone has shown significant improvements in progression-free survival in patients with chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin lymphoma. In clinical trials, this combination has demonstrated efficacy in both previously untreated patients and those with relapsed/refractory disease.
- Brand names
- ImbruvicaTreandaRituxan
- Other names
- Benda-R + ibrutinibBR + ibrutinib
02
Targets
ITK (Interleukin 2-inducible T-cell kinase)CD20 (B-lymphocyte antigen CD20)BTK (Bruton tyrosine kinase)DNA
Beyond the preview
Go deeper on bendamustine + rituximab + ibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bendamustine + rituximab + ibrutinib.